Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma

Talimogene Laherparepvec (T‐VEC) is a first‐in‐class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from a phase II study was used to develop a viral kinetic mechanistic model describing the interaction between cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahamadi, Malidi, Kast, Johannes, Chen, Po‐Wei, Huang, Xiaojun, Dutta, Sandeep, Upreti, Vijay V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931434/
https://www.ncbi.nlm.nih.gov/pubmed/36564918
http://dx.doi.org/10.1002/psp4.12898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931434/
https://www.ncbi.nlm.nih.gov/pubmed/36564918
http://dx.doi.org/10.1002/psp4.12898

Ejemplares similares